16 January 2018

Results of Clinical Trial for DAV132 Published in JID

Da Volterra announces the publication of full results of a clinical trial in humans for DAV132, a product to protect the microbiota from disruption by antibiotics and prevent C. difficile infections.


22 December 2017

Season's greetings!

Dear Colleagues, Partners and Friends,

Season's greetings to you and your family from Da Volterra! (...)

29 November 2017

In support of November C. diff Awareness Month Da Volterra announces complete QOL survey recruitment

In support of November proclaimed as “C. difficile Awareness” Month, Da Volterra is pleased to announce the end of the recruitment of a survey assessing the impact of C.difficile infections on (...)

16 November 2017

Da Volterra is a partner in the new COMBACTE-CDI consortium

Da Volterra is proud to join academic and EFPIA partners in the COMBACTE-CDI consortium which was launched in November 2017.

The COMBACTE consortium announces the addition of COMBACTE-CDI as a new project. The (...)

16 November 2017

Da Volterra is a signatory of the BEAM Alliance position paper

As part of our ongoing commitment to combating antibiotic resistance, Da Volterra has signed onto the BEAM Alliance position paper which calls out worldwide stakeholders to support SME-driven innovation and revive (...)

10 November 2017

Spread the News: European Antibiotic Awareness Day is Nov 15th and World Antibiotic Awareness Week is November 13-19!

Da Volterra strongly supports the World Antibiotic Awareness Week from November 13-19th and the European Antibiotic Awareness Day is November 15th.  To learn more about how to handle antibiotics with care, (...)

24 October 2017

Da Volterra Proudly Sponsors the 8th Annual Fight C. Diff Gala

The Peggy Lillis Foundation will hold the 8th Annual Fight C. Diff Gala November 3rd, 2017 in Brooklyn, NY and Da Volterra is very proud to sponsor this event which will additionally honor Dr. Clifford McDonald (...)

19 October 2017

Da Volterra is honored to sponsor the 5th Annual C.diff Awareness Conference

Da Volterra is committed to supporting innovation and growth to prevent C. difficile infections and is honored to sponsor the C. diff Awareness Conference and Health Expo organized by the C. diff Foundation (...)

22 September 2017

Da Volterra announces 20M€ from EIB to advance clinical development against antibiotic resistance

We are pleased to announce that the European Investment Bank (EIB) and our biopharmaceutical company, Da Volterra, have entered into a 20M€ financing agreement to support acceleration of the clinical (...)

4 September 2017

Da Volterra Demonstrates Prevention of Clostridium difficile Induced Death

Da Volterra, a biotechnology company located in Paris, France, is developing breakthrough therapies to combat antibiotic resistance and prevent Clostridium difficile infections (CDI) via protection of the (...)